Clinical Trial ResultsPositive top-line phase 1 data for oral once-daily GLP-1R agonist CT-996 in people with obesity without diabetes, shows 6.1% placebo-adjusted weight loss.
Financial PerformanceThe shares are expected to continue to outperform due to substantial earnings upgrade potential driven mostly by established franchises.
Sales GrowthExcluding the CV19 headwind, group, pharma, and diagnostics sales grew at highly respectable rates of 7%, 7% and 8% respectively.